CAGE Bio Announces $7.2M Series A Round

18 Feb, 2021

CAGE Bio Announces $7.2M Series A Round

– CAGE Bio from San Carlos is an innovative biotechnology company focused on developing innovative therapies for infection, inflammation and immunology.
– The company announced the closing of a $7.2m Series A financing.

Biotechnology Health Care Medical North America
Crunchbase icon

Content report

The following text will be sent to our editors: